Literature DB >> 35603904

Different human papillomavirus types share early natural history transitions in immunocompetent women.

Sally N Adebamowo1,2, Brian Befano2,3, Li C Cheung2, Ana Cecilia Rodriguez2, Maria Demarco2, Greg Rydzak3, Xiaojian Chen2, Carolina Porras4, Rolando Herrero4,5, Jane J Kim6, Philip E Castle2,7, Nicolas Wentzensen2, Aimée R Kreimer2, Mark Schiffman2, Nicole G Campos2,6.   

Abstract

Necessary stages of cervical carcinogenesis include acquisition of a carcinogenic human papillomavirus (HPV) type, persistence associated with the development of precancerous lesions, and invasion. Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS-LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabilities for health decision models. We excluded women with evidence of high-grade cervical abnormalities at any point during follow-up and restricted the analysis to incident infections in all women and prevalent infections in young women (aged <30 years). We used survival approaches accounting for interval-censoring to estimate the time to clearance distribution for 20 529 HPV infections (64% were incident and 51% were carcinogenic). Time to clearance was similar across HPV types and risk classes (HPV16, HPV18/45, HPV31/33/35/52/58, HPV 39/51/56/59 and noncarcinogenic HPV types); and by age group (18-29, 30-44 and 45-54 years), among carcinogenic and noncarcinogenic infections. Similar time to clearance across HPV types suggests that relative prevalence can predict relative incidence. We confirmed that there was a uniform linear association between incident and prevalent infections for all HPV types within each study cohort. In the absence of progression to precancer, we observed similar time to clearance for incident infections across HPV types and risk classes. A singular clearance function for incident HPV infections has important implications for the refinement of microsimulation models used to evaluate the cost-effectiveness of novel prevention technologies. Published 2022. This article is a U.S.Government work and is in the public domain in the USA.

Entities:  

Keywords:  HPV clearance; HPV incidence; HPV prevalence; early natural history of HPV

Mesh:

Year:  2022        PMID: 35603904      PMCID: PMC9329241          DOI: 10.1002/ijc.34128

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  43 in total

1.  Estimates of absolute cause-specific risk in cohort studies.

Authors:  J Benichou; M H Gail
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women.

Authors:  Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Stephen Cherne; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-20       Impact factor: 4.254

Review 3.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

4.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-02-15       Impact factor: 13.506

5.  Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.

Authors:  Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

Review 6.  The natural history of human papillomavirus infection.

Authors:  Silvia de Sanjosé; Maria Brotons; Miguel Angel Pavón
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2017-09-06       Impact factor: 5.237

7.  Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Authors:  Allan Hildesheim; Paula Gonzalez; Aimee R Kreimer; Sholom Wacholder; John Schussler; Ana C Rodriguez; Carolina Porras; Mark Schiffman; Mary Sidawy; John T Schiller; Douglas R Lowy; Rolando Herrero
Journal:  Am J Obstet Gynecol       Date:  2016-02-16       Impact factor: 8.661

8.  Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME's) Human Papillomavirus (HPV) and Cervical Cancer Study.

Authors:  Sally N Adebamowo; Eileen O Dareng; Ayotunde O Famooto; Richard Offiong; Olayinka Olaniyan; Kayode Obende; Amos Adebayo; Sanni Ologun; Bunmi Alabi; Peter Achara; Rasheed A Bakare; Michael Odutola; Oluwatoyosi Olawande; James Okuma; George Odonye; Ruxton Adebiyi; Patrick Dakum; Clement A Adebamowo
Journal:  Int J Epidemiol       Date:  2017-12-01       Impact factor: 7.196

9.  Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes.

Authors:  Sarah Wagner; David Roberson; Joseph Boland; Aimée R Kreimer; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Carolina Porras; Bernal Cortes; Joshua Sampson; Rolando Herrero; Ana Cecilia Rodriguez; Wim Quint; Leen-Jan Van Doorn; Allan Hildesheim; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

10.  Comprehensive Cervical Cancer Prevention in Tanzania (CONCEPT) study: Cohort profile.

Authors:  Bariki Mchome; Patricia Swai; Chunsen Wu; Johnson Katanga; Crispin Kahesa; Rachel Manongi; Julius D Mwaiselage; Susanne Kjaer; Vibeke Rasch; Ditte Søndergaard Linde
Journal:  BMJ Open       Date:  2020-09-18       Impact factor: 2.692

View more
  1 in total

Review 1.  Epidemiology and Molecular Biology of HPV Variants in Cervical Cancer: The State of the Art in Mexico.

Authors:  J Omar Muñoz-Bello; Adela Carrillo-García; Marcela Lizano
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.